AzTrials
AzTrials

Lung CancerCTS-POPNCT04369118

Efficacy Study of a Selective Chest Wall Restriction Belt in Postoperative of Lung Resection

A study testing Conventional follow-up and Conventional follow-up+chest wall restriction belt in people with Lung Cancer, run by University Hospital, Grenoble at 3 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to evaluate the efficacy of a new medical device in post-surgery of lung resection. The principle of this new device is based on selective chest wall restriction. This new modality of chest wall restriction is evaluated on patients in post-surgery for lung cancer. Read more about this study

Who is it for?
Ages 18 to 79 years
Conditions the study is for
Lung Cancer
What is being tested?
Conventional follow-up and Conventional follow-up+chest wall restriction belt
Could I receive a placebo?
No, everyone receives an active treatment
How many people
94 participants
Where
3 sitesFrance
Study dates
18 Nov 2020to 29 Feb 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 79 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with segmentectomy or lobectomy for lung cancer or lung cancer suspicious,
  • Surgical approach : video-assisted thoracic surgery (VATS) or thoracotomy,
  • Patients affiliated to social security or similarly regime,
  • Patients who gave their consent to participate in the study.

Who cannot join

  • Patients with outcomes of the pulmonary function test at the preoperative assessment : forced expiratory volume in one second (FEV1) or diffusing capacity of the lung for carbon monoxide (DLCO) > 45% predicted post-operative values and VO2max (maximal oxygen consumption) between 10 and 12 ml/kg/min,
  • Patients with a waist size > 120 cm
  • Patients with medical treatment for chronic pain (neuropathic pain,…)
  • Patients with tuberculosis or other pulmonary infectious pathology proven (aspergillosis, lung abscess, actinomycosis,…),
  • Patients carrying a resistant germs or extended-spectrum beta-lactamase (ESBL),
  • Paraplegic patients
Show all 10Show fewer
  • Patients with a diagnosed, progressive and/or uncontrolled neurological disease
  • Patients with a progressive psychosis or a serious psychotic history (hospitalization)
  • Patients who are in exclusion period of another interventional study
  • Protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health

Trial locations and contacts

3 sites in 1 country.

France3 sites
  • Assistance Publique Hôpitaux de Paris, Hôpital Avicenne

    Bobigny, 93000

  • Hôpital Louis Pradel

    Bron, 69500

  • CHU Grenoble Alpes

    Grenoble, 38043

Other trials in France

About this study

Official title: Efficacy Study of a Selective Chest Wall Restriction Belt in Postoperative of Lung Resection. A Multicenter, Prospective, Controlled, Randomized Study With Stratification on the Surgical Approach, Open With a Blind Analysis

The objective of this study is to evaluate the efficacy of a new medical device in post-surgery of lung resection. The principle of this new device is based on selective chest wall restriction. This new modality of chest wall restriction is evaluated on patients in post-surgery for lung cancer.

The hypothesis is that the use of this medical device would reduce the postoperative pain and increase the efficacy of cough and expectoration. The evolution of the operated patient would be better.

Read the detailed description

The present study is the first evaluation of the efficacy of a selective chest wall restriction belt.

The efficacy will be estimate on forced expiratory volume in one second (FEV1) at D3 by comparing 2 groups: a control group of patients with conventional follow-up and an experimental group of patients with conventional follow-up and a daily wear of the selective chest wall restriction belt after surgery.

Conditions
Lung Cancer
Being tested
Conventional follow-up, Conventional follow-up+chest wall restriction belt
Keywords
chest wall restriction, usability, lung surgery, medical device, pain, cough, expectoration
Medical subject headings
Lung Neoplasms, Pain, Cough

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Conventional follow-upProcedure or surgery

    Patients in this group benefit from conventional post-operative follow-up

  • Conventional follow-up+chest wall restriction beltDevice

    Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.

Study groups in NCT04369118
Study groupRoleWhat they receive
Conventional follow-up+chest wall restriction beltExperimentalPatients in this group benefit from conventional post-operative follow-up and wear the selective chest wall restriction belt in parallel. Patients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
Receives: Procedure: Conventional follow-up; Device: Conventional follow-up+chest wall restriction belt
conventional postoperative follow-upActive comparatorPatients in this group benefit from conventional post-operative follow-up . From Day 1 to Month 1
Receives: Procedure: Conventional follow-up

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of forced expiratory volume in one second (FEV1) between the two groups.

    Comparisons of forced expiratory volume in one second (FEV1) between the two groups at Day 3. The value of FEV1 is standardized with pre-operative one.

    Measured: 3 days

Secondary outcomes (12)
  1. Comparisons of pulmonary function test between the two groups

    Comparisons of pulmonary function test ( forced expiratory volume in one second (FEV1), Forced vital capacity (FVC)) between the two groups. They are expressed as Liters. Before surgery, all days from Day 2 to the patient's exit from hospital (max Day 6) and at the follow-up visit at Month 1. Each value is standardized with pre-operative one.

    Measured: 1 month

  2. Comparisons of Peak expiratory flow at cough between the two groups

    Comparisons of Peak expiratory flow at cough (PEF) between the two groups. It is expressed as Liters per second. Before surgery, all days from Day 2 to Day 6 and at the follow-up visit at Month 1. Each value is standardized with pre-operative one.

    Measured: 1 month

  3. Pain evaluation at rest and during cough: ENS scale

    The patient pain is evaluated using the ENS (Echelle Numérique Standard; standard digital scale, score between 0 to 10) for the two groups. The pain is evaluated all days from Day 2 to the patient's exit from hospital, at the weekly phone follow-up until Month 1 and at the follow-up visit at Month 1.

    Measured: 1 month

  4. Qualification of cough

    The cough is classified with this scale : 0-dry cough; 1-productive cough without expectoration; 2-productive cough with expectoration; 3-productive cough with important and/or difficult expectoration. It's qualified for the two groups all days from Day 2 to the patient's exit from hospital.

    Measured: 10 days

  5. Characterization of analgesic treatment.

    The analgesic drugs are characterized by their class, dose and number of dose taken in the two groups. These elements are evaluated all days from Day 2 to the patient's exit from hospital, at the weekly phone follow-up until Month 1 and at the follow-up visit at Month 1.

    Measured: 1 month

  6. Identification of using aerosol therapy, antibiotic therapy and loco-regional anaesthesia

    Use of aerosol therapy (yes/no) and class of drugs. Use of antibiotic therapy (yes/no), type of drugs and expected duration of treatment. Use of loco-regional anaesthesia (yes/no), modality of administration and type of drugs. These elements are evaluated all days from Day 2 to the patient's exit from hospital, at the weekly phone follow-up until Month 1 and at the follow-up visit at Month 1.

    Measured: 1 month

  7. Number and classification of post-surgery complications

    Number and classification of post-surgery complications.For the two groups from Day 1 to the follow-up visit at Month 1.

    Measured: 1 month

  8. The length of hospital stay

    The length of hospital stay in days for the two groups.

    Measured: 10 days

  9. Quantification of the quality of life evaluated with the EQ-5D-5L questionnaire

    The EQ-5D is a generic preference-based measure that indirectly measures the utility for health that generates an index-based summary score based upon societal preference weights. The EQ-5D-5L consists of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale (VAS) for health status. Each item has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The VAS ranges from 0 (worst health status) and 100 (best health status). Comparison between the two groups preoperatively, at the patient's exit from hospital, at Day 15 during the phone follow-up and at the follow-up visit at Month 1.

    Measured: 1 month

  10. Consumption of hospital care

    Comparions of the number of the consumption of hospital care (medical acts and consultations, rehospitalization) between the two groups from Day 1 to the follow-up visit at Month 1.

    Measured: 1 month

  11. Evaluation of medical device usability for patient

    Only for the medical device's group.

    1. Qualitative questionnaire specifically created about efficacy and acceptability of the medical device at the patient 's exit from hospital. This questionnaire uses Likert scale from 0 to 10 to evaluate each use step of the medical device, closed-ended questions and open questions for comments. A descriptive analysis will done with the answers
    2. Closed-ended questions will be asked in a questionnaire specifically created about acceptability and use of the medical device. A descriptive analysis will done with the answers and will be asked during the weekly phone follow-up.

    Measured: 1 month

  12. Evaluation of medical device usability for caregivers

    Only for the medical device's group. This questionnaire uses Likert scales from 0 to 10 to evaluate each use step ofthe medical device, closed-ended questions and open questions fr comments. It will be asked at the end of the clinical study at each caregiver.

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Apr 2020
  2. Study start18 Nov 2020
  3. Primary completion29 Feb 2024
  4. Study completion29 Feb 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
94 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04369118
Sponsor's protocol ID
38RC19.102
Acronym
CTS-POP
Status last verified
May 2024
First submitted
10 Mar 2020
Last updated
17 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Conventional follow-up and Conventional follow-up+chest wall restriction belt in people with Lung Cancer, run by University Hospital, Grenoble at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of forced expiratory volume in one second (FEV1) between the two groups. (time frame: 3 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in